Chong Kun Dang Pharmaceutical - Asset Resilience Ratio

Latest as of March 2026: 6.04%

Chong Kun Dang Pharmaceutical (185750) has an Asset Resilience Ratio of 6.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩110.67 Billion
≈ $75.00 Million USD Cash + Short-term Investments

Total Assets

₩1.83 Trillion
≈ $1.24 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Chong Kun Dang Pharmaceutical's Asset Resilience Ratio has changed over time. Check 185750 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Chong Kun Dang Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 185750 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩110.67 Billion 6.04%
Total Liquid Assets ₩110.67 Billion 6.04%

Asset Resilience Insights

  • Limited Liquidity: Chong Kun Dang Pharmaceutical maintains only 6.04% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Chong Kun Dang Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Chong Kun Dang Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 48.48%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 15.57%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%

Annual Asset Resilience Ratio for Chong Kun Dang Pharmaceutical (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Chong Kun Dang Pharmaceutical.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 7.24% ₩130.27 Billion
≈ $88.28 Million
₩1.80 Trillion
≈ $1.22 Billion
+2.18pp
2024-12-31 5.05% ₩73.70 Billion
≈ $49.95 Million
₩1.46 Trillion
≈ $988.58 Million
-5.32pp
2023-12-31 10.37% ₩145.42 Billion
≈ $98.55 Million
₩1.40 Trillion
≈ $950.41 Million
+6.95pp
2022-12-31 3.42% ₩38.44 Billion
≈ $26.05 Million
₩1.12 Trillion
≈ $762.32 Million
-1.89pp
2021-12-31 5.30% ₩55.52 Billion
≈ $37.63 Million
₩1.05 Trillion
≈ $709.33 Million
+1.27pp
2020-12-31 4.04% ₩38.20 Billion
≈ $25.89 Million
₩946.33 Billion
≈ $641.32 Million
+2.11pp
2019-12-31 1.93% ₩15.45 Billion
≈ $10.47 Million
₩801.35 Billion
≈ $543.06 Million
--
pp = percentage points

About Chong Kun Dang Pharmaceutical

KO:185750 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$597.37 Million
₩881.48 Billion KRW
Market Cap Rank
#11150 Global
#286 in Korea
Share Price
₩66900.00
Change (1 day)
-0.45%
52-Week Range
₩64100.00 - ₩97700.00
All Time High
₩207617.05
About

Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more